Trends in prostate cancer survival in Spain: results from population-based cancer registries

Abstract

In Spain the survival of patients with prostate cancer has increased significantly from 1999 to 2003, probably due to the advancement in diagnosis produced by the opportunistic screening of prostate-specific antigen (PSA). Differences in the dissemination and use of the PSA level could explain the observed geographic differences in the increase of survival. It would be necessary to carry out studies to quantify the produced overdiagnosis by screening with PSA in prostate cancer.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary

“…Compared with the National Cancer Registry [16], this study provides a good estimate for probability of 5-year OS (Table 2), and it is also in concordance with other data published in the medical literature [17][18][19][20][21]. The 5-year OS probability of breast cancer and especially colorectal cancer appears to be somewhat worse than some international references.…”

Future burden of prostate cancer mortality in Brazil: a population-based study

“…In these countries, mortality rates have declined during the last two decades, probably due to early diagnoses facilitated by the PSA testing and improvements in prostate cancer treatment 4,5,20 . Such a trend has also been observed in other South American countries, as is the case of Chile and Argentina.…”

“…The prostate-specific antigen (PSA) test was responsible, principally after the 1980s, for causing increases in incidence and survival rates for prostate cancer, as a consequence of early diagnosis 3,4 . However, the prevalence of PSA testing is relatively low in less developed countries, where Western influenced lifestyles have caused increases in prostate cancer rates 5 .…”

Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer

“…Asian prostate cancer patients had better survival but the incidence rate of PCa has been increasing rapidly in recent years [1]. Currently, radiation therapy is the main treatment for PCa and provides excellent local control and increased overall survival for PCa patients [2]. However, some PCa patients exhibit radiation resistance and develop metastatic disease in less than 5 years [3].…”